A Model for Others: A Strategy for Improving Diagnosis and Therapy of Human Malignancies Using Monoclonal Antibodies Targeting TAG72 Oncofetal Antigen

References

• Larson S M. Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J Nucl Med 1985; 26: 538–545
   PubMed Web of Science ®Google Scholar
• Sheer D G, Schlom J, Cooper H L. Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res 1988; 48: 6811–6818
   PubMed Web of Science ®Google Scholar
• Johnson V G, Schlom J, Paterson A J, Bennett J, Magnani J L. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by a monoclonal antibody B72.3. Cancer Res 1986; 46: 850–857
   PubMed Web of Science ®Google Scholar
• Nuti M, Teramoto Y A, Mariani-Constdntini R, Horan Hand P, Colcher D C, Schlom J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor associated antigen in human mammary carcinoma cell populations. Int J Cancer 1982; 29: 539–545
   PubMed Web of Science ®Google Scholar
• Thor A, Ohuchi N, Szpak C A, Johnston W W, Schlom J. The distribution of oncofetal antigen TAG-72 defined by monoclonal antibody B72.3. Cancer Res 1986; 46: 3118–3124
   PubMed Web of Science ®Google Scholar
• Colcher D C, Horan Hand P, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981; 78: 3199–3203
   PubMed Web of Science ®Google Scholar
• Reilly R M, Kirsch J, Gallinger S. Compartmental analysis of the pharmacokinetics of radioiodinated monoclonal antibody B72.3 in colon cancer patients. J Nucl Med 1992, in press
   Google Scholar
• Colcher D C, Esteban J, Carrasquillo J A. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 1987; 47: 4218–4224
   PubMed Web of Science ®Google Scholar
• Esteban J M, Colcher D C, Sugarbaker P. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer 1987; 39: 50–59
   PubMed Web of Science ®Google Scholar
• Colcher D C, Esteban J M, Carrasquillo J A. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 1987; 47: 1185–1189
   PubMed Web of Science ®Google Scholar
• Larson S M, Carrasquillo J A, Colcher D C. Estimates of radiation absorbed dose for intraperitoneally administered Iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatosis. J Nucl Med 1991; 32: 1661–1667
   PubMed Web of Science ®Google Scholar
• Carrasquillo J A, Sugarbaker P, Colcher D C. Peritoneal carcinomatosis: Imaging with intraperitoneal injection of [1–131]-labeled B72.3 monoclonal antibody. Radiology 1988; 167: 35–40
   PubMed Web of Science ®Google Scholar
• Schlom J, Colcher D C, Siler K, Thor A, Bryant G, Johnston W W. Tumor targeting with monoclonal antibody B72.3: Experimental and clinical results. Cancer Treat Res 1990; 51: 313–335
   PubMedGoogle Scholar
• Riva P, Marangolo M, Lazzari S, Agostini M, Sarti G. Locore-gional inmunotherapy of human ovarian cancer: Preliminary results. Int. J Radiat Appl Instrument 1989; 16: 659–666
   PubMedGoogle Scholar
• Lastoria S, Salvatore M. Monoclonal antibody B72.3 immunoscintigraphy in the follow-up of patients with colorectal cancer. Targeted Diagn Ther 1992; 657–71
   Google Scholar
• Salvatore M. lmmunoscintigraphy with radiolabeled antibodies: An overview of the progress and limitations. J Nucl Biol Med 1991; 35: 21–23
   PubMedGoogle Scholar
• Mansi L, Panza N, Lastoria S, Pacilio G, Salvatore M. Diagnosis of ovarian cancer with radiolabelled monoclonal antibodies. Int J Radiat Appl Instrument 1989; 16: 127–135
   PubMedGoogle Scholar
• Salvatore M, Lastoria S, Del Vecchio S, Mansi L. Detection of colon cancer with radiolabelled monoclonal antibodies. Int J Radiat Appl Instrument 1989; 16: 103–104
   PubMedGoogle Scholar
• Renda A, Salvatore M, Sava M, Landi R, Lastoria S, Coppola L. Immunoscintigraphy in the follow-up of patients operated on for carcinoma of the sigmoid and rectum. Preliminary report with a new monoclonal antibody B72.3. Dis Colon Rectum 1987; 30: 683–686
   PubMed Web of Science ®Google Scholar
• Martin E W. Intraoperative radioimmunodetection of occult tumor: Past. present. Pathol Biol 1990; 38: 317–818
   Google Scholar
• Sardi A, Workman M, Mojzisik C, Hinkle G, Nieroda C, Martin E W. Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS). Arch Surg 1989; 12: 55–59
   Google Scholar
• Lange M K, Martin E W. Monoclonal antibodies in imaging and therapy of colorectal cancer. World J Surg 1991; 15: 617–622
   PubMed Web of Science ®Google Scholar
• La Valle GJv, Chevinsky A, Martin E W. Impact of Radioimmunoguided surgery. Semin Surg Oncol 1991; 7: 167–170
   PubMed Web of Science ®Google Scholar
• Nieroda C A, Mojzisik C, Hinkle G, Thurston M O, Martin E W. Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer. Cancer Detect Prev 1991; 15: 225–229
   PubMedGoogle Scholar
• Cohen A M, Martin E W, Lavery I, Daly J, Sardi A, Aitken D. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Sure 1991; 126: 349–352
   PubMed Web of Science ®Google Scholar
• Martin E W, Hinkle G, Mojzisik C, Thurston M O. Radioimmunoguided surgery: A new intraoperative approach to the detection of tumors. Cancer Treat Res 1990; 51: 387–411
   PubMedGoogle Scholar
• Martin E W, Mojzisik C M, Hinkle GH, Jr, Sampsel J, Siddiqi M A. Radioimmunoguided surgery using monoclonal antibody. Am J Surg 1988; 156: 386–392
   PubMed Web of Science ®Google Scholar
• Martin E W, Tuttle S E, Rousseau M, Mojzisik C M, Odwyer P J. Radioimmunoguided surgery: Intraoperative use of monoclonal antibody. Hybridoma 1986; 5: S97–108, Suppl 1
   PubMed Web of Science ®Google Scholar
• Schlom J, Siler K, Colcher D C, Carrasquillo J A, Reynolds J C. Binding of radiolabeled MAb B72.3 administered intravenously and intraperitoneally in colorectal patients: An overview. Acta Radiol 1990; 374: 123–128
   Google Scholar
• Esteban J M, Schlom J, Gansow O A, Atcher R W, Brechbiel M W. New method for the chelation of indium-I II to monoclonal antibodies. J Nucl Med 1987; 28: 861–870
   PubMed Web of Science ®Google Scholar
• Roselli M, Schlom J, Gansow O A, Raubitschek A, Mirzadeh S. Comparative biodistributions of yttrium-and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1989; 30: 672–682
   PubMed Web of Science ®Google Scholar
• Gansow O A, Brechbiel M W, Mirzadeh S, Colcher D C, Roselli M. Chelates and antibodies: Current methods and new directions. Cancer Treat Res 1990; 51: 153–171
   PubMedGoogle Scholar
• Schlom J, Siler K, Milenic D E. Monoclonal antibody based therapy of human tumor xenograft with a lutetium-177 labeled immunoconjugate. Cancer Res 1991; 51: 2889–2896
   PubMed Web of Science ®Google Scholar
• Hutzell P, Kashmiri S, Colcher D C, Primus F J, Hand P H. Generation and characterization of a recombinant/chimeric B72.3. Cancer Res 1991; 51: 181–189
   PubMed Web of Science ®Google Scholar
• Khazaeli M B, Saleh M N, Liu T P. Pharmacokinetics and immune response of 1311-chimeric mouseihuman B72.3 (human-4) monoclonal antibody in humans. Cancer Res 1991; 51: 5461–5466
   PubMed Web of Science ®Google Scholar
• Maguire R T, Schmelter R F, Pascucci V L, Conklin J J. Imniunoscintigraphy of colorectal adenocarcinoma: Results with site-specifically radiolabeled B72.3 (In-III CYT-103). Antibody Immunoconjugates Radiopharm 1989; 2: 257–269
   Google Scholar
• Rosenblum M G, Kavanaugh J J, Burke T W. Clinical pharmacology, metabolism, and tissue distribution of yttrium-90 labeled monoclonal antibody B72.3 after intraperitoneal administration. J Natl Cancer Inst 1991; 83: 1629–1636
   PubMed Web of Science ®Google Scholar
• Muraro R, Kuroki M, Wunderlich D, Poole D J, Colcher D, Thor C. A. Generation and characterization of B72.3 second generation monoclonal. Cancer Res 1988; 48: 4588–4596
   PubMed Web of Science ®Google Scholar
• Colcher D C, Minelli M F, Roselli M, Muraro R, Simpson-Milenic D, Schlom J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 1988; 48: 4597–4603
   PubMed Web of Science ®Google Scholar
• Schlom J, Eggensperger D, Colcher D C, Molinolo A, Houchcns D. Therapeutic advantage of high-affinity anticarcinoma radioim-munoconjugates. Cancer Res 1992; 52: 1067–1072
   PubMed Web of Science ®Google Scholar
• Schlom J, Hand P H, Greiner J W. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res 1990; 50: 820s–827s, Suppll
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Carrasquillo J A, Chang A E. Differences in biodistribution of indium-III-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer. J Nucl Med 1989; 30: 320–327
   PubMed Web of Science ®Google Scholar
• Greiner J W, Guadagni F, Noguchi P, Pestka S., Colcher D C. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 1987; 235: 895–898
   PubMed Web of Science ®Google Scholar
• Greiner J W, Gyuadagni F, Goldstein D. Intraperitoneal administration of interferon-gamma to carcinoma patients cnhances expression of tumor-associated glycoprotein-72 and car-cinoembryonic antigen on malignant ascites cells. J Clin Oncol 1992; 10: 735–746
   PubMed Web of Science ®Google Scholar
• Esteban J M, Schlom J, Mornex F, Colcher D C. Radioimmunotherapy of athymic mice bearing human colon carcinomas. Eur J Cancer Clin Oncol 1987; 23: 643–655
   PubMedGoogle Scholar
• Schlom J, Molinolo A, Simpson J F, Siler K, Roselli M, Hinkle G. Advantage of dose fractionation in monoclonal antibody-targeted. J Natl Cancer Inst 1990; 82: 763–771
   PubMed Web of Science ®Google Scholar
• Milenic D E, Yokota T, Filpula D R. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1992; 51: 6363–6371
   Web of Science ®Google Scholar
• Bird R E, Hardman K D, Jacobson J W. Single chain antigen binding proteins. Science 1988; 242: 423–426
   PubMed Web of Science ®Google Scholar
• Colcher D C, Bird R, Roselli M, Hardman K D, Johnson S, Pope S. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990; 82: 1191–1197
   PubMed Web of Science ®Google Scholar
• Yokota T, Milenic D E, Whitlow M, Schlom J. Rapid tumor penetrance of a single chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992
   Web of Science ®Google Scholar
• Mach J P, Buchegger F, Pelegrin A, Bischof-Delaloye A, Delaloye B. Progress in radiolabeled monoclonal antibodies for cancer diagnosis and potential for therapy. Accomplishments in Cancer Research, JG Fortner, JE Rhoads. Lippincott, Philadelphia 1990; 222–256
   Google Scholar